Figure 1

CCX771, in combination with IR, reduces tumour size and prevents tumour recurrence in mice containing U251 GBM tumours. U251 GBM cells were implanted intracranially into mice (day 0), and a subset of the mice was given 12 Gy whole-brain IR 3 weeks later. All mice were then treated once daily with the CXCR7 inhibitor CCX771 (30 mg kg⁻¹) or its vehicle for 3 weeks. Neither CCX771 nor the vehicle affected the tumours in non-irradiated mice. In combination with IR, however, CCX771 significantly inhibited tumour growth (P<0.05 compared with vehicle). The tumours in irradiated mice treated with the vehicle remained the same size for 7 weeks, but started to grow thereafter. The tumours in irradiated mice treated with CCX771 regressed over the course of the study (n=6 mice).